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Abstract Previous studies have indicated that acid-optimal cys- 
teine proteinase(s) in the endosomal-lysosomal compartments, 
cathepsins, play a critical role in the proteolytic processing of 
endocytosed proteins to generate the antigenic peptides presented 
to the immune system on major histocompatibility complex 
(MHC) class II molecules. The presentation of these peptides and 
the expression of MHC class II molecules by macrophages and 
lymphocytes are stimulated by y-interferon (y-IFN). We found 
that treatment of human U-937 monocytes with y-IFN increased 
the activities and the content of the two major lysosomal cysteine 
proteinases, cathepsins B and L. Assays of protease activity, 
enzyme-linked immunosorbant assays (ELISA) and immunoblot- 
ting showed that this cytokine increased the amount of cathepsin 
B 5-fold and cathepsin L 3-fold in the lysosomal fraction. By 
contrast, the aspartic proteinase, cathepsin D, in this fraction was 
not significantly altered by y-IFN treatment. An induction of 
cathepsins B and L was also observed in mouse macrophages, but 
not in HeLa cells. These results suggest coordinate regulation in 
monocytes of the expression of cathepsins B and L and MHC 
class II molecules. Presumably, this induction of cysteine pro- 
teases contributes to the enhancement of antigen presentation by 
y-IFN. 
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1. Introduction 
Antigen-presenting cells (APCs) display on their surface 
membranes peptides derived from endocytosed proteins in 
complexes with class II major hystocompatibility complex 
(MHC) molecules [1,2]. This step is a critical early event in 
eliciting antibody production and inflammatory responses. An- 
tigen presentation on class II molecules (in contrast to the 
presentation of intracellular antigens on MHC class I mole- 
cules) is restricted to certain cells, especially monocytes and 
macrophages. In these cells, the presented peptides are gener- 
ated from the endocytosed proteins by limited proteolytic di- 
gestion in the endosomal or lysosomal compartments. Before 
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binding the antigenic peptides, the newly synthesized MHC 
class II molecules form a complex in the endoplasmic reticulum 
with the invariant chain (Ii), which stabilizes the MHC mole- 
cules and facilitates their transport into the acidic endosomal- 
lysosomal compartments. There, the inhibitory invariant chain 
undergoes proteolytic inactivation, which exposes the binding 
site on the MHC molecules [3]. The proteolytic events that 
generate the antigenic peptides and inactivate the invariant 
chains in these compartments depend on the decreased pH, the 
reducing environment [4], and the activities of the various lyso- 
somal proteinases, known as cathepsins. However, the precise 
roles of different endosomal-lysosomal proteinases in antigen 
presentation and the mechanisms that regulate the activities of 
these proteases and prevent the complete digestion of the anti- 
genie peptides are still unclear. 
Among the most prominent lysosomal proteases are cathep- 
sin D, an aspartic proteinase which has its optimum activity in 
the very acidic range (pH 3.54.5), and the cysteine proteases, 
cathepsin B and cathepsin L, which degrade proteins optimally 
in the pH range from 4.5-6.5. There is a growing series of 
observations indicating a critical role of these cysteine proteases 
in class II presentation. Takahashi et al. [5] and Diment [6], 
using inhibitors, demonstrated in vivo that cysteine proteinases 
were clearly important for the proteolytic processing of bovine 
albumin by APCs, even though the aspartic proteinase, cathep- 
sin D, was able to degrade this antigen in vitro into fragments 
that could be recognized by Thl lymphocytes. Recently, To- 
watari et al. [7], also using selective inhibitors, showed that a 
cysteine proteinase, in particular cathepsin B, is critical in the 
processing of recombinant hepatitis B antigenic subtype 
(HBsAG) by APCs. Other studies [8] provided evidence that the 
processing of different polypeptides may require digestion by 
distinct proteases to reveal antigenic epitopes. Using protease 
inhibitors to modulate the ability of splenic APC and B cell 
hybridoma to present chicken ovalbumin (OVA), Vidard et al. 
[9,10] demonstrated that the endosomal-lysosomal proteases 
have the capacity to both generate and destroy immunogenic 
peptides, and that different epitopes on the same protein may 
be processed in distinct fashions by different APCs. In fact, in 
epithelial cells, cathepsin E had been shown to play a critical 
role in the elicitation of IgA responses [1 I]. 
MHC class II antigen presentation is under the control of the 
interferons (IFNs), a family of antiviral immune modulatory 
proteins that regulate the expression of a large number of cellu- 
lar genes [12]. All three types of IFNs induce MHC class I 
expression, but only y-IFN also stimulates class II presentation 
[1,3,13,14]. It was demonstrated recently [15] that y-IFN acts 
by inducing the transactivator gene, CIITA, which directly 
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controls both the constitutive and inducible MHC class II ex- 
pression. In stimulating class II presentation, y-IFN may also 
enhance expression of other genes in the APC in addition to 
MHC class II molecules. The stimulation by y-IFN of MHC 
class I presentation involves the increased expression of class 
I molecules, peptide transporters on the endoplasmic reticulum, 
and the LMP2 and LMP7 proteins which function as subunits 
of the 20 S and 26 S proteasome [16,17]. The incorporation of 
these y-IFN-induced subunits in the proteasome, enhances cer- 
tain peptidase activities and suppresses others [ 13,15-171. As a 
result, the degradation of cytosolic proteins by the ubiquitin- 
proteasome pathway should yield more of the types of oli- 
gopeptides that were transported selectively into the ER [l&19] 
and that bind preferentially to class I molecules [16,17]. 
The present studies were undertaken to test the possibility 
that the stimulation of MHC class II presentation by y-IFN 
may also involve an alteration in the proteolytic capacity of the 
lysosomal-endosomal compartment, analogous to the changes 
in the proteases that generate peptides for MHC class I presen- 
tation. We have tested whether, in the class II system, I/-IFN 
treatment may change the content of lysosomal proteases and 
thus may alter the pattern of protein digestion of endocytosed 
proteins. This study demonstrates for the first time that expo- 
sure to y-IFN causes the selective enhancement of the expres- 
sion and activities of cathepsins B and L in human and mouse 
monocyte lines, which could have important consequences for 
MHC class II antigen presentation. 
2. Materials and methods 
2.1. Cell cultures and y-IFN treatment 
U-937 (human hystiocytic lymphoma, ATCC CRL 1593) cells 
(0.15 x 106/ml) were grown in RPM1160 medium containing 10% fetal 
calf serum (FCS) and antibiotics at 37°C for 72 h with and without 
1,000 U/ml human recombinant y-IFN, which was kindly provided by 
Biogen Inc., Cambridge, MA. This concentration of y-IFN was found 
to cause maximal stimulation of MHC class I antigen presentation and 
maximal alteration in proteasomal peptidase activities [16]. A3.1A.7 is 
an immortalized mouse macrophage cell line [20]. HeLa cells were 
obtained from American Type Culture Collection (Rockville, MD) and 
grown in DME medium in the presence of 10% fetal calf serum. 
2.2. Subcellular fractionation 
Macrophages were collected by centrifugation for 5 min at 700 x g, 
washed twice and resuspended in the homogenization buffer, contain- 
ing 50 mM Tris, 5 mM MgCI,, 1 mM dithiothreitol (DTT), 2 MM ATP, 
250 mM sucrose at pH 7.4. Cell suspensions were homogenized using 
a Dounce homogenizer (Wheaton), followed by vortexing for 3 min 
with glass beads. The crude extracts were obtained by centrifugation 
at 10,000 x g for 20 min and a further centrifugation at 100,000 x g for 
1 h to obtain the microsomal pellet and the soluble (cytosolic) fraction, 
which was the source of proteasome fraction used in previous studies 
[16]. The ‘low speed pellets’ from the crude extracts (sedimenting at 
10,000 x g), which contained nuclear and lysosomal particles, and the 
microsomal pellets (the ‘high speed pellets’ sedimenting at 100,000 x g) 
were extracted with 50 mM Tris buffer, containing 0.5% Triton X-100 
and 1 mM EDTA. They were homogenized with 5 passages in a Potter- 
Elvehjem (Teflon) homogenizer, and centrifuged in an Ultracentrifuge 
(Beckman) at 100,000 x g for 30 min to obtain the clear supernatants 
used for the biochemical analyses. 
Alternatively, in many experiments, the monocytes were disrupted by 
nitrogen cavitation and homogenized with the Dounce homogenizer. 
Cell debris and nuclear pellets were separated by a centrifugation at 
1.500 x p for 10 min. The supernatant was centrifuged at 12,000 x I: for 
26 min to obtain the lysosome-endosome-enriched fraction (the ‘12K 
pellet’), which was extracted in 50 mM Tris buffer, containing 0.5% 
Triton X-100 and used for analysis. Further centrifugation ofthe super- 
natant at 100,000 x g min for 60 min resulted in the microsomal pellets 
and the soluble supernatant (cystosolic fraction), which was also stud- 
ied in parallel. 
2.3. Enzyme activity assays 
Cathepsin D was determined by the Anson procedure for determina- 
tion of aspartic proteases, using hemoglobin as a substrate, as modified 
by Turk et al. [16]. Cathepsin B activity assay [lS] was modified as 
described in details previously [19]. Briefly, 20 ~1 of the sample were 
added to 280 ~1 of the activation buffer containing 400 mM phosphate 
buffer, pH 6.0, containing 4 mM EDTA and 1.2 mM dithiothreitol and 
pre-incubated for 5 min at 37”C, before the substrate, 100 ~1 Z-Ala- 
Arg-Arg-7-AMC (Z-ARR-AMC) (Bachem, PA, USA), was added. 
After 150 min incubation, the reaction was stopped with cold 1 mM 
iodoacetic acid. The linearity of Cat B activity for 240 min at 37°C in 
crude homogenates has been established (unpublished data). Blanks 
were prepared without the addition of the enzyme. Samples and con- 
trols, containing 1 mM L-epoxy succinylleucyllamido-(4-guanidine)- 
butane (E-64) were carried out in duplicate. Fluorescence was read at 
an excitation wavelength of 370 nm and an emission wavelenght of 460 
nm in an SLM Aminco S2 Luminescence Spectrophotometer and 
standardized against AMC. Cathepsin L activity was assayed after the 
samples were pre-incubated for 3 h at 37°C in 34 mM acetate buffer, 
pH 4.2, containing 2 mM dithiothreitol and 1 mM EDTA. Each enzyme 
activity assay was performed in triplicate. 
Cathepsin L activity was measured using Z-Phe-Arg-AMC (Z-FR- 
AMC) as the substrate in the presence and absence of the selective 
inhibitor, Z-Phe-Phe-CHN, (Enzyme System Products), as described 
previously [21]. After preincubation at 37°C in acetate buffer at pH 4.2 
to activate Cat L precursor, as described in detail by Mason et al. [22], 
lOO@ of 0.34 mM acetate buffer, pH 5.5, containing 1 mM EDTA and 
1.3 mM DTT, were added, followed by 100 ~1 of 2 mM inhibitor 
solution to a final volume of 400 ~1. Control samples received 100 ~1 
of water instead of the inhibitor, and the reaction was started by adding 
100 ~1 of the substrate solution to each sample. The reaction was 
stopped after 150 min incubation at 37°C by 500 ~1 of 1 mM iodoace- 
tate. Cathepsin L enzyme units were calculated as described above for 
cathepsin B. The difference in fluorescence between the samples and the 
controls represented cathepsin L activity. These activities are expressed 
in EU/g protein, where 1 EU represents the amount of enzyme releasing 
1 prnol of 7-AMC per min. Protein concentration was determined by 
the Bradford method (Bio-Rad, USA) using bovine serum albumin as 
the standard [23]. 
2.4. Enzyme-protein immunochemical determination 
Cathepsin D was measured in the extracts by the competitive enzyme 
immunosorbent-linked assay (ELISA) obtained from Triton Diagnos- 
tics (CA, USA). The assay recognizes all forms of the enzyme (total 
enzyme mass) using the combination of monoclonal anti-human 
cathepsin D antibody and rabbit polyclonal antibody, both specific for 
cathepsin D. Cathepsins B and L protein content were determined by 
a double-sandwich ELISA (BioAss, Diessen, Germany) using immuno- 
specific polyclonal rabbit and sheep anti-human cathepsin B antibodies. 
According to the protocol (BioAss), both immunoassays detected all 
free enzyme forms (precursor and active forms), as well as their com- 
plexes with the endogenous inhibitors. 
2.5. SDS-PAGE and immunoblotting 
Slab-gel electrophoresis was carried out in 10% polyacrylamide gels 
in the presence of SDS followed by blotting on nitrocellulose mem- 
branes, as described by Towbin et al. [24]. For immunoblotting, pro- 
teins separated by SDS-PAGE were transferred electrophoretically to 
nitrocellulose membranes, using a BioRad Trans-Blot apparatus. The 
blots were incubated with the polyclonal primary antibodies and with 
goat secondary antibodies, conjugated with horseradish peroxidase 
(Pierce, USA) and detected using a silver-gold enhancement kit (Amer- 
sham, USA), as recommended by the manufacturer. Primary polyclo- 
nal rabbit antibodies for cathepsin B, generously given by Dr. Joza 
Babnik (Jozef Stefan Institute, Ljubljana, Slovenia), were used in a 
1: 250 dilution. Immunospecific polyclonal sheep antibod- 
ies, raised against human brain cathepsin D, kindly provided by Dr. 
Ralph Nixon (McLean Hospital-Harvard Medical School, MA, USA), 
were used in a 1 :400 dilution. 
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3. Results 
3.1. Cathepsin activities in monocytes and HeLa cells 
To define the lysosomal-endosomal compartment, we meas- 
ured the specific activities of the lysosomal proteinases, cathep- 
sins B and L, in all subcellular fractions from the human mac- 
rophage line, U937, and the mouse monocyte line, A3.1A.7. 
These two lysosomal markers were found to be greatly enriched 
in the lO_12,OOOxg pellets: Cathepsin B activity in various 
preparations of this fraction was 9- to 45-fold higher than in 
microsomal pellets, and at least 500-fold higher than in the 
100,000 x g supernatant (Table 1). Cathepsin L activity was 
enriched 2- to 5-fold in various preparations of the 12,000 x g 
pellet over the 100,000 x g pellets and at least 200-fold over the 
soluble supernatant. Therefore, in subsequent experiments, the 
rapidly sedimenting pellets were used to measure proteases in 
the lysosomal compartment. 
Human monocytes were harvested after treatment with or 
without y-IFN for 3 days, and the activities of cathepsins B, L 
and D were measured in the 10,000 x g or 12,000 x g pellets. 
Large increases were observed in the activities of both cysteine 
proteases in the cell lines grown in the presence of human 
y-IFN, compared to control cells grown in parallel without the 
cytokine (Table 2). The mean increases in cathepsin B were 
4.5fold in the 10,000 x g pellets and 6.2-fold in the 12,000 x g 
pellets. Similarly, the mean activity of cathepsin L increased 
4.6-fold in both pellets. By contrast, no significant changes were 
observed in cathepsin D activity, although the content of this 
enzyme was at the lower limit of sensitivity of the hemoglobin- 
degradation method (data not shown). 
To test if these findings on the human macrophage line were 
also found in all human cell lines, HeLa cells were treated with 
y-IFN in a similar fashion. In these cells, y-IFN is known to 
induce a number of genes [16,17] and to stimulate MHC class 
I antigen presentation [ 13,171. No significant change in cathep- 
sin B and L activities was observed in HeLa cells exposed to 
I/-IFN under conditions where the cytokine did induce MHC 
class I molecules and the MHC encoded proteasome subunits, 
LMPl and LMP2 [16]. We, therefore, tested if this response 
might be restricted to monocytes, which do play a prominent 
role in class II presentation. Table 2 shows that treatment of 
mouse macrophages with murine y-IFN for several days en- 
hanced the activities of both cathepsin B and L approximately 
2-fold. These changes appeared smaller than those seen with 
U937 cells. However, the human cytokine was used at concen- 
trations determined previously to cause maximal changes in 
Table 1 
The activities of cathepsins B and L in subcellular fractions of U937, 
a human macrophage cell line 
Subcellular fraction Activity (EU/g) 
Endosomal-lysosomal 
(12,000 x g pellet) 
Microsomal 
(100,000 x g pellet) 
Soluble supernatant 
Cathepsin B 
450 
10 
0.63 
Cathepsin L 
150 
37 
0.6 
A representative experiment is shown with the extracts of different 
subcellular fractions, obtained from human monocytes (U937), as de- 
scribed in section 2. Specific enzyme activities were measured as de- 
scribed previously [21,22] and in section 2. 
Table 2 
Effects of y-interferon treatment on cathepsin B and L activities in the 
endosomal-lysosomal fraction of human (U937), mouse (A3.1Al.7) 
and HeLa cells 
Preparation Activity (EU/g; mean rt SD.) 
Cathepsin B Cathepsin L 
U937 cells 
12,000 x g pellets 
Control 
+ y-IFN 
Mean ratio (n = 3) 
10,000 x ,g pellets 
Control 
+ y-IFN 
Mean ratio (n = 7) 
A3.1Al.7 
12,000 x g pellets 
Control 
+ y-IFN 
Mean ratio (n = 3) 
HeLa cells 
12,000 x g pellets 
Control 
+ y-IFN 
Mean ratio (n = 3) 
720 f 10 
4507 f 3 
6.2 
240 f 129 
802 + 140 
4.5 
427 f 50 
1006 + 150 
2.2 
1467 f 190 
1382 f 642 
1.1 
746 f 34 
1803 f 26 
2.4 
20.2 f 5.6 
92.5 f 35 
4.6 
4666 f 593 
10762 f 1007 
2.1 
1263 + 590 
1287 + 204 
0.9 
Cathepsin activities were determined in endosomal-microsomal frac- 
tions, defined as either the 12,000 x g or as 10,000 x g pellets (in certain 
initial experiments on U937 cells), obtained from (n) independent prep- 
arations. In each, the cells were cultured with or without human y-IFN 
for 3 days. Mean ratios were obtained in (n) pairs of control and treated 
cells, which were cultured and prepared in parallel. The extracts were 
prepared as described in section 2, and specific enzyme activities of 
cathepsins B and L, using fluorigenic substrates, were measured as 
described [22,23]. 
U937 cells, while the most effective concentrations of the mur- 
ine y-IFN have not been determined. 
3.2. Cathepsin content in human monocytes 
)I-IFN may increase the activities of the cysteine proteinases 
in extracts either by increasing the amount of these enzymes or 
by activation of these proteases or by decreasing the level of the 
endogenous inhibitors, cystatins. To investigate whether y-IFN 
treatment increased the amounts of cathepsins D, B and L, we 
measured the content of all three proteases immunochemically 
by ELISAs (Table 3). In human macrophages, cathepsin D was 
present in the highest concentration, followed by cathepsins L 
and B. Only the concentration of the cysteine proteinases were 
affected by y-IFN treatment. The protein content of these 
cathepsins was not determined in the mouse monocytes, be- 
cause the ELISAs are designed to measure only the proteases 
of human origin. These changes resembled the increase in en- 
zyme activities described above. 
This effect of y-IFN on cathepsin B content in macrophages 
was confirmed using immunoblotting (Fig. 1). The lysosomal 
fraction from U937 cells treated with and without I/-IFN were 
normalized for protein concentration and applied to SDS- 
PAGE. A marked increase in the cathepsin B band was ob- 
served; in human macrophages, its heavy chain appeared as a 
darker, double bank with an M, of 25,000 and 27,000, as was 
also noted in other cell lines [25]. In accord with the assays of 
enzyme activities, immunoblotting with anti-human cathepsin 
D antibodies showed no difference between the y-IFN-treated 
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and control samples in the intensity of the major protein band, 
which corresponds to the IV, 3 1,000 heavy chain of the mature 
cathepsin D form. Together, these findings indicate that y-IFN 
enhances cathepsin B and L activities by stimulating the pro- 
duction of these proteins. 
St Yl Yl Yl Yl 
4. Discussion 
The present studies have demonstrated for the first time a 
selective regulation of the protease content of lysosomes by the 
cytokine, I/-IFN. This agent caused a large increase in cathepsin 
B and a moderate increase in cathepsin L in macrophages, while 
the other abundant lysosomal protease, cathepsin D, did not 
change. It is of particular interest that these findings were 
restricted to macrophages, which play a major role in antigen 
presentation on MHC class II molecules, and were not seen in 
HeLa cells, which do not present on class II molecules. This 
selective response is also noteworthy because of the special role 
of macrophages in phagocytosis of microbial pathogens and 
antigen-antibody complexes and in the killing of neoplastic 
cells. It seems likely that this increase in the content of cathepsin 
B and L in macrophages by y-IFN is important in enhancing 
the proteolytic processing of the endocytosed antigens for pres- 
entation to the immune system or in the inactivation of the 
inhibitor Ii chains. Possibly, this increase in protease content 
may also enhance the macrophage’s ability to digest the endo- 
cytosed materials and the tumoricidal activity of tumor-infil- 
trating macrophages. For example, the marked anti-neoplastic 
effects of y-IFN, e.g. in regression of local recurrences of breast 
carcinoma [26], appears to be due in part to the activation of 
tumor-infiltrating macrophages, which show a marked increase 
in expression of MHC class I and class II. 
The proposed role of cysteine proteinases in antigen process- 
ing [558] is supported by recent observations that cathepsin B 
can produce peptide fragments bearing T-cell epitopes from 
recombinant human growth factor [27] and from IgG2a in vitro 
[28]. Most direct evidence for the involvement of cathepsin B 
in the humoral response to vaccination with hepatitis-B type 
(HBsAg) was recently provided by Matsunaga et al. [7,29], who 
showed that selective inhibition of cathepsin B can block this 
process, while inhibition of cathepsin L or cathepsin H could 
not. Our finding that this protease is induced when class II 
presentation is accelerated and when y-IFN production rises 
are thus of particular interest. 
The selective induction of cathepsins B and L, together with 
Table 3 
Effects of y-Interferon treatment on the content of cathepsins D, B, L 
proteins in lysosomal-endosomal fraction of human U937 macrophages 
Preparation 
Activity (ng/mg) 
Cathepsin D Cathepsin B Cathepsin L 
Control 
y-IFN 
Mean ratio 
(n = 3) 
5340 f 1700 188 f 25 25 f 20 
6185 k 1250 440 f 240 110 f 83 
1.1 2.4 4.4 
Cathensins concentrations were measured bv ELISAs. as described in 
section 2 and expressed per mg of total protein in ‘the endosomal- 
lysosomal preparation. Mean values of three measurements of cathep- 
sins in controls and y-IFN-treated cell lines are presented. Mean ratio 
was obtained in pairs of control and treated cells, which were cultured 
simultaneously. 
33 
27 
A 
Fig. 1. Immunoblotting of cathepsins D and B in endosomal-lysosomal 
fraction of human monocyte U 937 cell line. Immunoblotting was 
carried out according to Towbin [25] and as described in details in 
section 2. (A) Immunostaining with polyclonal antibodies, raised 
against human cathepsin B, resulted in double band of cathepsin B 
heavy chain at M, 25,000-27,000 in endosomal-lysosomal pellets 
(10,000 x g). First lane represents standard human cathepsin B (Medor, 
Hersching, Germany). Lanes represent four matched pairs grown with- 
out or with y-IFN. (B) Immunostaining with polyclonal antibodies, 
raised against human cathepsin D, stained most intensively the heavy 
chain of mature Cat D at M, 31,000. The intensity of the staining did 
not differ in five matched pairs of 10,000 pellets prepared from treated 
and control samples of human macrophages. A typical matched pair 
is shown. 
MHC class II proteins, suggests that y-IFN regulates the pro- 
teolytic activity necessary for the partial digestion of endocy- 
tosed proteins to the types of peptides that can be presented on 
class II. An increase in protease content could either enhance 
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or reduce production of an antigenic peptide depending on the 
polypeptide, the sequences of the antigenic epitope, and the 
selectivity of cathepsins B and L. Recently, a domain in the 
invariant chain of the class II molecules was reported to share 
an extensive sequence homology with the cystatins, the en- 
dogenous inhibitors of cysteine proteases [30]. Interestingly, the 
invariant chain Ii strongly inhibited cathepsins H and L, but not 
B [7,30]. Moreover, a fragment of the Ii (p 41 li) has been found 
associated with cathepsin L and thus may block its activity in 
lysosomes in vivo [31]. It is conceivable that cathepsin L specif- 
ically binds this fragment of Ii after its cleavage and release 
from the class II complexes. This hypothesis may also account 
for the observations by McCoy et al. [32], who found that an 
excess of cathepsin L precursor, added to cell culture media and 
internalized together with the protein antigen, inhibited antigen 
presentation. Presumably, this inhibition was due to excessive 
proteolysis not counterbalanced by the endogenous Ii frag- 
ments (and/or cystatins), and resulting in complete cleavage of 
antigen epitopes. 
I/-IFN also stimulates the presentation of cytosolic antigens 
on the MHC class I pathway, in part due to a modification of 
proteasome activity, which results in the generation of more 
peptides that end with hydrophobic (and basic) residues. Such 
peptides are more readily transported into the ER [33,34] and 
selectively bind to surface MHC class I molecules [4,16,17,35]. 
The present observations suggests that y-IFN may act in an 
analogous way in the MHC class II pathway to alter the enzy- 
matic content and proteolytic cleavage patterns of lysosomes. 
Interestingly, Matsunaga et al. [29] have noted structural simi- 
larities between the active endoproteolytic site on cathepsin B 
and the peptide-binding region of MHC class II molecules. 
Thus, this protease may be particularly important in determin- 
ing the carboxyl-terminus of the presented peptide. By inducing 
cathepsin B, y-IFN may favor production of those types of 
peptides that bind preferentially to MHC class II. Very re- 
cently, Nadler et al. [36] have reported that the pattern of 
peptides generated by monocytes from endocytosed albumin 
does differ significantly after treatment with y-IFN. It remains 
to be established whether this modulation of the way proteins 
are processed is of importance for immunological responses 
and whether it is due to the induction of cathepsins B and L. 
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